2024
Novel multi-modal methodology to investigate placebo response in major depressive disorder
Cusin C, Dillon D, Belleau E, Normandin M, Petibon Y, El-Fakri G, Dhaynaut M, Hooker J, Kaptchuk T, McKee M, Hayden E, Meyer A, Jahan A, Origlio J, Ang Y, Brunner D, Kang M, Long Y, Fava M, Pizzagalli D. Novel multi-modal methodology to investigate placebo response in major depressive disorder. Journal Of Affective Disorders 2024, 368: 1-7. PMID: 39233242, DOI: 10.1016/j.jad.2024.08.226.Peer-Reviewed Original ResearchPlacebo responseDepressive disorderRates of placebo responseMesocorticolimbic dopaminergic pathwayExpectation of rewardAntidepressant responseMesolimbic systemReward circuitryNeurobiological underpinningsNeurobiological mechanismsDopaminergic activityDopaminergic systemPlacebo respondersSymptom reductionDopaminergic pathwaysMulti-modal methodologyPlacebo phenomenonPsychological constructsTreatment developmentMDDPlacebo-controlledClinical trialsDouble-blindRewardDesigning clinical trials
2022
A multi-pronged investigation of option generation using depression, PET and modafinil
Ang Y, Cusin C, Petibon Y, Dillon D, Breiger M, Belleau E, Normandin M, Schroder H, Boyden S, Hayden E, Levine M, Jahan A, Meyer A, Kang M, Brunner D, Gelda S, Hooker J, Fakhri G, Fava M, Pizzagalli D. A multi-pronged investigation of option generation using depression, PET and modafinil. Brain 2022, 145: 1854-1865. PMID: 35150243, PMCID: PMC9166534, DOI: 10.1093/brain/awab429.Peer-Reviewed Original ResearchConceptsD2/D3 receptor availabilitySelf-generated optionsDepressive disorderDepressed individualsReceptor availabilityDopamine D2/D3 receptor availabilityNon-depressed adultsEffects of modafinilPutamen of patientsAssociated with uniquenessOption generationD2/D3 receptorsDopaminergic activityClinical depressionBinding potentialModafinilHealthy participantsPutamenPlacebo-controlledSamples of healthy peopleDouble-blindDisordersSelf-generationHealthy controlsDopamine